
US Pharmaceutical Pipeline Expands With Innovation and Competition
2025 is expected to bring a number of new traditional and specialty pharmaceuticals, including the first generic and biosimilar competitors for blockbuster brands and innovative therapies for cancer and neurological disorders, according to 2 presentations …